Lumos Pharma Announces Changes to its Board of Directors


AUSTIN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the appointment of An van Es-Johansson, M.D., to its Board of Directors, effective immediately, where she will serve as a member of the Nominating and Governance Committee. Dr. van Es-Johansson brings over 30 years of experience in executive and clinical development roles in the pharmaceutical industry. Dr. van Es-Johansson will succeed Emmett Cunningham who is resigning his Board position to focus on other professional obligations in his managerial role at Blackstone Life Sciences.

“We are excited to welcome Dr. An van Es-Johansson to our Board,” said Rick Hawkins, CEO, President and Chairman. “Dr. van Es-Johansson’s clinical and corporate experience focused on growth hormone disorders and other rare diseases will be of immense value to Lumos Pharma as we pursue our clinical and business development programs targeting this same area. We also greatly appreciate Emmett Cunningham’s tenure as a Lumos Pharma Board member. His guidance served Lumos Pharma well, particularly through our transition last year to a publicly listed company, and we wish Emmett the very best in his ventures hereafter.”

“I am pleased to have been able to assist the company in advancing its clinical and corporate strategy,” commented Emmett Cunningham. “Dr. van Es-Johansson’s extensive experience in the pharmaceutical industry will be an asset to the Lumos Board, and I feel confident that she will guide the company successfully through its next stage of development.”

Dr. An van Es-Johansson is the Chief Medical Officer and Head of Development for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease and will transition to a Senior Advisor role on March 1, 2021. Dr. van Es-Johansson’s early work in the life science industry focused on the clinical development of recombinant human growth hormone (rhGH) therapeutics for Turner Syndrome and other endocrine disorders at both Eli Lily and Pharmacia Upjohn. From 2005-2018, Dr. van Es-Johansson served in a range of executive roles of increasing responsibility at Sobi, an international rare disease company headquartered in Stockholm, Sweden. Dr. van Es-Johansson has leadership experience within large pharmaceutical and smaller biotechnology companies, including Roche, Active Biotech, and BioStratum. From 2004-2016 she was a member of the Scientific Advisory board for Uppsala Bio and currently serves on the Board of Directors at Medivir AB, Savara Pharmaceuticals, PLUS Therapeutics, and Agendia BV. Dr. van Es-Johansson received a M.D. from Erasmus University, Rotterdam, The Netherlands.

“I am thrilled to join Lumos Pharma’s Board of Directors at this exciting time as the company advances its Phase 2b trial evaluating a novel oral therapeutic for pediatric growth hormone deficiency,” Dr. van Es-Johansson stated. “I look forward to working with the Board and the Lumos management team as the company pursues this clinical program and embarks on a path toward expanding its pipeline in rare diseases.”

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.